ClinicalTrials.gg
CompletedNCT01431820SOLUTIONUpdated Nov 30, 2015

Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis

A Phase 2/3 interventional study of Luliconazole Solution, 10% and Vehicle Solution in Distal and Lateral Subungual Onychomycosis, sponsored by Topica Pharmaceuticals. Completed at 28 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-11-30.

Sponsored by Topica Pharmaceuticals · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
334
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies in Onychomycosis with a site in United States — 3 open to participants now, 7 under way, 1 of them phase 3. Onychomycosis · United States.

Enrollment
16th of 75
334 · median 50
Started
2012
the only one that year
Phase 2/3
3 of 77
none open now
Registered
38th of 77
by date

Among the 77 studies in Onychomycosis with a site in United States, this one is the 16th largest by enrollment of the 75 interventional ones that give a count, is the only one that started in 2012, is one of 3 in phase 2/3, and was the 38th registered.

Onychomycosis

158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.

Browse Onychomycosis studies →

Open to participants now

3 of the 77 studies in Onychomycosis with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Onychomycosis studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Onychomycosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of a topical antifungal formulation, Luliconazole Solution, 10%, in the treatment of adults with onychomycosis of the toenails.

03

Conditions studied

  • Distal and Lateral Subungual Onychomycosis

Browse trials for

Keywords

  • Onychomycosis
  • Toenail Fungus
  • luliconazole
  • Antifungal
  • Topical
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects of either gender, any race and between the ages of 18 and 70 inclusive
  • Subjects with a clinical diagnosis with culture confirmation of distal subungual onychomycosis (DSO) - Subjects must be free of any disease that in the Investigator's opinion might interfere with the study evaluations or jeopardize the subject's safety

Exclusion criteria

Exclusion Criteria:

  • Subjects with a history of intolerance or to imidazole compounds or the inactive components of the solution
  • Subjects who are currently participating or have recently participated in another medication or device study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
334 participants (actual)

Study arms

  • Experimental
    Luliconazole Solution, 10% Regimen 1

    Drug: Luliconazole Solution, 10%

  • Experimental
    Luliconazole Solution, 10% Regimen 2

    Drug: Luliconazole Solution, 10%

  • Placebo comparator
    Vehicle Solution Regimen 1

    Drug: Vehicle Solution

  • Placebo comparator
    Vehicle Solution Regimen 2

    Drug: Vehicle Solution

Interventions

  • DrugLuliconazole Solution, 10%

    Topical

  • DrugVehicle Solution

    Topical

06

What researchers measure

Primary outcomes

  1. The proportion of subjects who achieve complete cure of the target great toenail

    Time frame: Week 52

07

Study locations

28 sites
  • Phoenix, Arizona 85050, United States
  • Los Angeles, California 90045, United States
  • San Diego, California 92119, United States
  • San Diego, California 92123, United States
  • Denver, Colorado 80210, United States
  • Aventura, Florida 33180, United States
  • Miami, Florida 33175, United States
  • Boise, Idaho 83704, United States
  • Evansville, Indiana 47714, United States
  • Louisville, Kentucky 40202, United States
  • Baltimore, Maryland 21214, United States
  • Detroit, Michigan 48202, United States
  • Fridley, Minnesota 55432, United States
  • Albuquerque, New Mexico 87106, United States
  • East Setauket, New York 11733, United States
  • Rochester, New York 14623, United States
  • Cincinnati, Ohio 45249, United States
  • Portland, Oregon 97210, United States
  • Portland, Oregon 97223, United States
  • Knoxville, Tennessee 37922, United States
  • Nashville, Tennessee 37215, United States
  • Austin, Texas 78759, United States
  • College Station, Texas 77840, United States
  • Dallas, Texas 75243, United States
  • San Antonio, Texas 78229, United States
  • Salt Lake City, Utah 84117, United States
  • Lynchburg, Virginia 24501, United States
  • Madison, Wisconsin 53719, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Jun 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2011
First posted
Sep 12, 2011
Start
May 2012
Primary completionActual
Jun 2014
CompletionActual
Aug 2014
Results delay requested
Nov 2, 2015
Last update
Nov 30, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01431820
Lead sponsor
Topica Pharmaceuticals
Responsible party
Sponsor
First posted
Sep 12, 2011
Start date
May 2012
Primary completion
Jun 2014
Completion
Aug 2014
Last update
Nov 30, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion